NCT01167712
Clinical Trial Information
Trial Number: NCT01167712 (ClinicalTrials.gov)
Disease Type:
- Reproductive System Neoplasm, Female - Ovarian Cancer (excluding Ovarian Germ Cell Cancer)
Trial Title:
A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Study ID:
GOG-0262
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01167712-D5 | There are 5 data submissions associated with PMID 26933849. This dataset contains the reason(s) for treatment delay in trial NCT01167712. |
| NCT01167712-D4 | There are 5 data submissions associated with PMID 26933849. This dataset contains treatments administered at each cycle from NCT01167712. |
| NCT01167712-D3 | There are 5 data submissions associated with PMID 26933849. This dataset contains the maximum grade of adverse events experienced by subjects in NCT01167712. |
| NCT01167712-D2 | There are 5 data submissions associated with PMID 26933849. This dataset contains quality of life (QoL) data from trial NCT01167712. |
| NCT01167712-D1 | There are 5 data submissions associated with PMID 26933849. This dataset contains the treatment comparison between dose-dense versus weekly Paclitaxel and Carboplatin in trial NCT01167712. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®